Ortataxel

Drug Profile

Ortataxel

Alternative Names: BAY 59-8862; IDN 5109; SBT 101131

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Indena; State University of New York
  • Developer Indena; Spectrum Pharmaceuticals
  • Class Antineoplastics; Polycyclic bridged compounds; Taxanes
  • Mechanism of Action P-glycoprotein inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Solid tumours
  • Discontinued Non-Hodgkin's lymphoma; Renal cell carcinoma

Most Recent Events

  • 20 Jul 2017 Ortataxel is still at phase II development stage for Solid tumours in USA (PO) (IV) (Spectrum Pharmaceuticals website, July 2017)
  • 09 Jun 2015 Ortataxel is still in phase II for Solid tumours in USA (PO, IV)
  • 09 Jun 2015 Ortataxel is available for licensing in Europe, Asia (excluding USA) - http://www.sppirx.com/340-spectrum-products-out-licensing.html
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top